Independent education resourceInformation here does not replace care from a qualified health professional.
Peptide Therapy GuideClear peptide education

Educational guide

Pharmalot, Pharmalittle: Vertex and Ireland battle over price of cystic fibrosis drug

H ello, everyone, and how are you today? We are just fine, thank you, despite the gloomy clouds hovering over the Pharmalot campus. After all, the glass is half full, even if some believe it is just a stupid glass. In any event, we are forging ahead with plans

Written by Peptide Therapy Guide Editorial Team
For education only

This guide cannot diagnose a condition or recommend a personal treatment plan. Discuss medical questions with a qualified professional.

H ello, everyone, and how are you today? We are just fine, thank you, despite the gloomy clouds hovering over the Pharmalot campus. After all, the glass is half full, even if some believe it is just a stupid glass. In any event, we are forging ahead with plans to talk to interesting people and forage for fascinating items to hold your attention. On that note, we also welcome juicy tips and unredacted documents. Meanwhile, here are some tidbits. Have a grand day and do stay in touch … Ireland’s Health Service Executive and Vertex Pharmaceuticals appear ready to resume talks about the price of the Orkambi cystic fibrosis drug , the Irish Times reports. The National Center for Pharmacoeconomics, the national watchdog agency, says that Orkambi is too expensive at the price demanded by Vertex, which is about $170,000 annually. Hundreds of people have protested outside government offices this week seeking access to the treatment. President-elect Donald Trump is weighing naming a staunch libertarian as the next Food and Drug Administration commissioner , STAT writes. Jim O’Neill, who works for Peter Thiel, the billionaire Trump donor, once called for eliminating the agency mandate to determine whether new medicines are effective before approving them for sale. He is not a physician, and lacks the strong science background most former commissioners have had. STAT+ Exclusive Story Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.

Already have an account? Log in

Individual plans

Group plans

View All Plans

To read the rest of this story subscribe to STAT+.

Subscribe

Connected reading

Helpful context for this guide

Source-derived material selected through this article’s indexed topics.

Related questions

01Are there any risks to the test?

There is no known risk to a sweat test. The electrode may cause a tingling or tickling sensation from the electric current, but this is not painful.

Source: medlineplus.gov ↗
02What is cystic fibrosis? A Mayo Clinic expert explains

Learn more from pulmonologist Sarah Chalmers, M.D. Cystic fibrosis (CF) is a condition passed down in families that causes damage to the lungs, digestive system and other organs in the body. CF affects the cells that make mucus, sweat and digestive juices. These fluids, also called secretions, are usually thin and slippery to protect the body's internal tubes and ducts and make them smooth pathways. But in people with CF, a changed gene causes the secretions to become sticky and thick. The secretions plug up pathways, especially in the lungs and pancreas. CF gets worse over time and needs daily care, but people with CF usually can attend school and work. They often have a better quality of life than people with CF had in past decades. Better screening and treatments mean that people with CF now may live into their mid- to late 50s or longer, and some are being diagnosed later in life.

Source: www.mayoclinic.org ↗
03How Strong Is the Evidence for Alyftrek?

Based on the current clinical studies, Alyftrek is a safe and effective treatment for people with cystic fibrosis. The Cystic Fibrosis Foundation published a CFTR modulator therapy care guideline in 2018. Alyftrek is not included in these guidelines since it was approved by the FDA after these guidelines were published.

Source: www.webmd.com ↗
04What Are the Symptoms of Cystic Fibrosis?

The symptoms of cystic fibrosis vary. Some children will have symptoms at birth, while others may not have symptoms for weeks, months, or even years. The severity of symptoms also varies, with some children showing only mild digestive and lung problems and others having severe food-absorption problems and life-threatening breathing complications. The most common symptoms of cystic fibrosis are: Salty-tasting skin , which parents notice when they kiss their child Frequent coughing , wheezing , or bouts of pneumonia or sinusitis Difficulty breathing that keeps getting worse Big appetite but poor weight gain Bulky, smelly, greasy bowel movements Over time, the symptoms of cystic fibrosis can worsen and may include: Chronic productive cough, recurrent lung infections Obstructive lung disease ( emphysema ) Chronic nasal congestion and sinus infections Pancreatitis , a painful inflammation of the pancreas Liver disease Diabetes Gallstones

Source: www.webmd.com ↗
05What you can do

You might want to take a friend or family member with you to the appointment to help you remember information. Before your appointment, make a list of: Symptoms and when they started. Include anything that makes symptoms worse or better. All medicines, vitamins, herbs and supplements that you or your child take. Include the doses. Family history, such as whether anyone in your family has cystic fibrosis. Treatment you or your child have had for CF, if any. Include what the treatment was and if it helped. Any other medical conditions and their treatments. Questions to ask your healthcare professional. Questions to ask may include: What is likely causing these symptoms? What kinds of tests are needed? What treatment do you recommend? I or my child have other health conditions. How will cystic fibrosis affect them? Are there any limits needed? Feel free to ask other questions during your appointment.

Source: www.mayoclinic.org ↗
Research context

Read sources and limitations before applying a claim.

Research and Statistics: Who Has Cystic Fibrosis?

About 40,000 people are living with cystic fibrosis in the United States, and there are approximately 105,000 people with CF worldwide. (3) More than 75 percent of people with the disease are diagnosed by age 2, and more than half of all people living with cystic fibrosis are 18 or older. CF occurs predominantly in white populations, at a rate of 1 in 2,500 births. Between 2 and 5 percent of white people are carriers of the CFTR gene variant but have no overt clinical signs of disease. The disease is less common among African Americans, occurring at the much lower frequency of approximately 1 out of 17,000 births. (15) CF gene variants are most prevalent in persons of northern and central European ancestries or of Ashkenazi Jewish descent. They are rarely found in Native Americans, Asians, or native Africans. (16) CF is equally common among men and women, but women patients fare significantly worse than male patients with the disease. The median survival age for female CF patients is about three years younger than it is for men, but the reasons for the poorer survival rates among women are not completely understood. (17)

Source: everydayhealth.com ↗
P

About the author

Peptide Therapy Guide Editorial Team

Editorial team for Peptide Therapy Guide.

View all articles →